These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15483738)

  • 21. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical study of the month. The CHARM study].
    Kulbertus H
    Rev Med Liege; 2003 Oct; 58(10):646-52. PubMed ID: 14677527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS
    J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials.
    Sica DA
    Congest Heart Fail; 2004; 10(3):160-4. PubMed ID: 15184734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding heart failure with preserved ejection fraction: clinical importance and future outlook.
    Miller AB; Piña IL
    Congest Heart Fail; 2009; 15(4):186-92. PubMed ID: 19627293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candesartan cilexetil in the treatment of chronic heart failure.
    Baguet JP; Barone-Rochette G; Neuder Y
    Vasc Health Risk Manag; 2009; 5(1):257-64. PubMed ID: 19436650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candesartan cilexetil: a review of its use in the management of chronic heart failure.
    Fenton C; Scott LJ
    Drugs; 2005; 65(4):537-58. PubMed ID: 15733014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.
    McKelvie RS
    Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):9-16. PubMed ID: 19105762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
    Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
    JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Candesartan cilexetil: an update.
    Joost A; Schunkert H; Radke PW
    Expert Opin Pharmacother; 2011 Aug; 12(11):1769-80. PubMed ID: 21651457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
    Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
    Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin inhibition in heart failure.
    McMurray JJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
    Pocock SJ; McMurray JJ; Dobson J; Yusuf S; Granger CB; Michelson EL; Ostergren J; Pfeffer MA; Solomon SD; Anker SD; Swedberg KB
    Eur Heart J; 2008 Nov; 29(21):2641-50. PubMed ID: 18819960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
    Shah RV; Desai AS; Givertz MM
    J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial.
    Takahama H; Asakura M; Abe Y; Ajioka M; Aonuma K; Anzai T; Hayashi T; Hiramitsu S; Kawai H; Kioka H; Kimura K; Lim YJ; Matsuoka K; Motoki H; Nagata Y; Nakamura S; Ohte N; Ozaki Y; Sasaoka T; Tamaki S; Hamasaki T; Kitakaze M;
    Cardiovasc Drugs Ther; 2018 Aug; 32(4):381-388. PubMed ID: 29974299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.